Resource | Description | Cystic Fibrosis | Controls w/o CF | # of samples/ sections | Start Date | Contact | Related Grants/Studies |
---|---|---|---|---|---|---|---|
Airway and Lung Parenchyma | Tissue from explanted lungs from patients with CF; typically processed within 24 -48 hours post-surgery | 33 | 2009 | Moira Aitken, MD Pradeep Singh, MD | Singh, CFF SINGH11GO | ||
Pancreatic sections | Pancreatic autopsy tissue sections from patients with cystic fibrosis, with and without CF related diabetes, and non-CF controls with and without Type II diabetes | 43 | 55 | 25 sections per participant, 1075 CF; 1375 non-CF | 2012 | Rebecca Hull, PhD | Hull, P30 DK089507 -Pilot |
Stool | Stool samples collected longitudinally over 12 month period from infants and young children; refrigerated after collection; frozen at -80 C within 24 – 72 hours | 15 | 13 | 140 | 2011 | Luke Hoffman, MD, PhD | Hoffman, P30 DK089507 - Pilot |
Saliva | Stimulated and unstimulated saliva collected and frozen at -80 C within 24 hours after collection. | 30 | 60 | 2014 | Donald Chi, DDS, PhD | Chi, CFF R565-CR11 – Pilot | |
Expectorated Sputum | Spontaneously expectorated sputum collected longitudinally for 3 observational trials; refrigerated at 4 C after collection and stored at -80 C within 24 – 48 hours after collection | 45 | 120 | 2011 | Luke Hoffman, MD, PhD | Hoffman, CFF – HOFFMA11A0 | |
Expectorated Sputum | Spontaneously expectorated sputum collected longitudinally for 3 observational trials; refrigerated at 4 C after collection and stored at -80 C within 24 – 48 hours after collection | 54 | 587 | 2009 | Pradeep Singh, MD | Singh, K24 HL102246 R01 HL110879 R01 AI101307 |
|
Expectorated Sputum | Spontaneously expectorated sputum collected longitudinally for 3 observational trials; refrigerated at 4 C after collection and stored at -80 C within 24 – 48 hours after collection | 12 | 41 | 2013 | Pradeep Singh, MD | Singh, R01 AI101307 |
|
Microbial DNA preps | Microbial DNA preps available from explanted lungs | 8 | 115 | 2009 | Pradeep Singh, MD | Singh, K24 HL102246, CFF SINGH11GO, |
|
Bacterial Isolates | Bacterial populations isolated from expectorated sputum samples (96 isolates per “population”) | 54 | 406 bacterial populations including 27 from patients with exacerbation; 144 from patients during antibiotic treatment | 2009 | Pradeep Singh, MD | Singh, K24 HL102246 R01 HL110879, R01 AI101307 |
|
Bacterial isolates | Populations of bacterial isolates cultured from explanted lung tissue of upper, middle and lower lobes and lingula | 13 | 131 populations from 10 lungs | 2009 | Pradeep Singh, MD | Singh, CFF SINGH11GO | |
Bacterial Isolates | Populations of P. aeruginosa isolates from 8 CF subjects with the G551D genotype prior to (day 0) and after (days 2, 8, 90, 210, 420) receiving ivacaftor | 8 | 41 populations of 96 isolates each from 8 subjects | 2013 | Pradeep Singh, MD | ||
Serum | Samples banked at multiple time points during oral glucose tolerance testing; frozen at -80 C | 11 | 66 | 2014 | Ron Gibson, MD, PhD | Motaghedi, SCRI Academic Excellence Fund | |
Historical Biospecimens | |||||||
Bacterial Isolates | Longitudinal clinical bacterial isolates (P. aeruginosa, S. aureus [MSSA, MRSA, SCV], S maltophilia, Achromobacter spp., B. cepacia complex), cultured from upper and lower respiratory specimens and explanted lung tissue from individual patients cared for at SCH and UWMC; sources detailed in Micro Core and described on the CFRTC website | All isolates from individuals with CF | Over 30,000 clinical isolates | Jane Burns, MD | |||
Bacterial Isolates | Isolates of P. aeruginosa, S. aureus [MSSA, MRSA, SCV], S maltophilia, Achromobacter spp., and B. cepacia complex derived from 14 observational and interventional studies processed in the TDN Center for CF Microbiology at Seattle Children’s; specific studies detailed in Micro Core Table 1 and described on CFRTC website. | All isolates from individuals with CF | 9500 isolates from 14 clinical trials | Jane Burns, MD | Micro core isolates derived from 14 clinical trials |
||
Ordered transposon mutant library of Pseudomonas aeruginosa | Created a near-saturation sequence defined transposon mutant library in which individual mutants are arrayed and can be retrieved for distribution. 'Random' transposon insertion mutants were arrayed and sequenced to define the transposon insertion locations in the genome of P. aeruginosa strain PA01. | 9437 | Kiara Held | ||||
Serum | Longitudinal serum samples collected pre, during post therapeutic intervention in a multicenter clinical trial in pediatric patients | 66 | 1715 aliquots | Ron Gibson, MD, PhD | Ramsey and Gibson, IT 004 Clinical Trial | ||
Bronchoalveolar lavage (BAL) | BAL collected pre- and post- therapeutic intervention in a multicenter clinical trial in pediatric patients | 44 | 1215 aliquots | Ron Gibson, MD, PhD | Ramsey and Gibson, IT 004 Clinical Trial | ||
Data Repository | |||||||
Research clinical data | Data from 21 Phase 3 multi-center trials involving over 3000 patients; described on the CFRTC website | > 3000 | TDN contact: Sonya Heltshe |